百诚医药
(301096)
| 流通市值：24.29亿 | | | 总市值：38.21亿 |
| 流通股本：6943.03万 | | | 总股本：1.09亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 392,889,024.57 | 428,969,485.2 | 242,990,244.62 | 615,453,537.69 |
| 应收票据及应收账款 | 380,904,163.26 | 361,493,394.86 | 396,769,547.15 | 357,939,297.23 |
| 其中：应收票据 | - | - | 6,953,658.37 | 3,962,578.5 |
| 应收账款 | 380,904,163.26 | 361,493,394.86 | 389,815,888.78 | 353,976,718.73 |
| 应收款项融资 | 5,760,493.94 | 3,250,272 | - | - |
| 预付款项 | 41,889,424.15 | 32,357,746.62 | 66,917,635.61 | 42,948,810.94 |
| 其他应收款合计 | 3,031,579.57 | 3,157,565.24 | 3,166,591.28 | 3,355,563.75 |
| 存货 | 197,381,307.81 | 177,342,362.44 | 149,222,182.01 | 152,317,234.62 |
| 合同资产 | 390,159,165.61 | 379,655,510.32 | 437,813,625.17 | 416,383,215.68 |
| 其他流动资产 | 78,416,138.87 | 76,248,021.61 | 75,192,042.95 | 62,787,668.02 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,610,431,297.78 | 1,545,474,358.29 | 1,591,071,868.79 | 1,734,845,327.93 |
| 非流动资产: | | | | |
| 长期股权投资 | 35,051,746.66 | 35,051,746.66 | 17,569,709.37 | 16,434,086.48 |
| 其他非流动金融资产 | 157,728,119.59 | 152,728,119.59 | 132,352,267.6 | 132,352,267.6 |
| 固定资产 | 1,609,519,638.42 | 1,621,776,057.19 | 1,602,659,648.9 | 1,631,351,042.66 |
| 在建工程 | 212,810,303.55 | 206,659,919.37 | 191,329,105.54 | 172,690,064.76 |
| 使用权资产 | 3,132,325.8 | 3,303,617.77 | 3,476,884.05 | 990,845.65 |
| 无形资产 | 92,481,772.93 | 93,427,530 | 91,879,377.35 | 104,830,567.06 |
| 长期待摊费用 | 1,286,828.82 | 1,415,780.02 | 53,258.94 | 359,662.53 |
| 递延所得税资产 | 37,135,902.54 | 35,549,469.71 | 63,803,027.79 | 61,640,131.69 |
| 其他非流动资产 | 14,307,940.72 | 25,801,916.9 | 65,708,534.65 | 57,132,568.77 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,163,454,579.03 | 2,175,714,157.21 | 2,168,831,814.19 | 2,177,781,237.2 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,773,885,876.81 | 3,721,188,515.5 | 3,759,903,682.98 | 3,912,626,565.13 |
| 流动负债: | | | | |
| 短期借款 | 530,186,724.48 | 360,080,773.64 | 558,819,577.78 | 633,876,063.89 |
| 应付票据及应付账款 | 119,406,291.59 | 147,360,248.89 | 132,207,373.76 | 173,379,471.92 |
| 其中：应付票据 | 19,577,721.73 | 12,466,139.14 | 17,610,319.29 | 49,809,932.55 |
| 应付账款 | 99,828,569.86 | 134,894,109.75 | 114,597,054.47 | 123,569,539.37 |
| 合同负债 | 115,993,383.58 | 112,423,760.7 | 92,728,456.94 | 90,796,615.51 |
| 应付职工薪酬 | 19,349,665.07 | 26,949,952.1 | 22,948,324.49 | 22,882,193.67 |
| 应交税费 | 2,783,878.09 | 10,172,609.19 | 9,245,049.83 | 12,603,115.16 |
| 其他应付款合计 | 4,461,284.63 | 7,406,253.15 | 5,244,974.86 | 7,930,504.38 |
| 一年内到期的非流动负债 | 54,412,099.65 | 104,985,634.89 | 706,866.19 | 392,254.03 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 846,593,327.09 | 769,379,232.56 | 821,900,623.85 | 941,860,218.56 |
| 非流动负债: | | | | |
| 长期借款 | 244,170,937.99 | 244,000,000 | 40,030,000 | 40,022,500 |
| 租赁负债 | 3,242,822.88 | 2,918,855.48 | 3,049,950.59 | 848,805.68 |
| 预计负债 | 97,175,112.67 | 94,015,691.22 | 91,393,309.88 | 92,187,347.7 |
| 递延收益 | 29,543,859.02 | 31,484,951.96 | 33,426,044.9 | 37,014,137.84 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 374,132,732.56 | 372,419,498.66 | 167,899,305.37 | 170,072,791.22 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,220,726,059.65 | 1,141,798,731.22 | 989,799,929.22 | 1,111,933,009.78 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 109,228,284 | 109,228,284 | 109,228,284 | 108,919,903 |
| 资本公积 | 2,106,813,173.52 | 2,106,813,173.52 | 2,102,747,583.59 | 2,141,014,635.99 |
| 减:库存股 | 49,998,224.77 | 49,998,224.77 | 49,998,224.77 | 49,998,224.77 |
| 其他综合收益 | -175,418.9 | -143,069.59 | -133,938.4 | -136,694.88 |
| 盈余公积 | 54,614,142 | 54,614,142 | 54,459,951.5 | 54,459,951.5 |
| 未分配利润 | 332,677,861.31 | 358,875,479.12 | 553,428,612.54 | 545,982,993.38 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,553,159,817.16 | 2,579,389,784.28 | 2,769,732,268.46 | 2,800,242,564.22 |
| 少数股东权益 | - | - | 371,485.3 | 450,991.13 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,553,159,817.16 | 2,579,389,784.28 | 2,770,103,753.76 | 2,800,693,555.35 |
| 负债和股东权益合计 | 3,773,885,876.81 | 3,721,188,515.5 | 3,759,903,682.98 | 3,912,626,565.13 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-29 | 2024-08-15 |
| 审计意见(境内) | | 标准无保留意见 | | |